Mechanisms of aspirin-sensitive respiratory disease - A two-compartment model

International Archives of Allergy and Immunology

Volumn 142, Issue 1, 2006, Pages 59-63

  Farooque, Sophie ^a   Lee, Tak ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; G PROTEIN COUPLED RECEPTOR; LIPOXIN A; LIPOXYGENASE INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; STEM CELL FACTOR;

ASPIRIN SENSITIVE RESPIRATORY DISEASE; ASTHMA; BRONCHOSPASM; COMPARTMENT MODEL; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EDITORIAL; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; NOSE CONGESTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; RHINORRHEA; RHINOSINUSITIS; SMOOTH MUSCLE FIBER; SYMPTOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ASPIRIN; ASTHMA; CYCLOOXYGENASE INHIBITORS; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RESPIRATORY TRACT DISEASES;

EID: 33845956551     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095999     Document Type: Editorial

References (52)

1. Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res 2003;110:255-258.
2. Widal MF, Abrami P, Lenmoyez J: Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-192.
3. Samter M, Beers RF Jr: Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-983.
4. Stevenson DD, Simon RA: Sensitivity to aspirin and other non-steroidal anti-inflammatory drugs; in Middleton E Jr, Reed CE, Ellis EF, et al (eds): Allergy: Principles and Practice, ed 5. St Louis, Mosby-Year Book, 1998, pp 1747-1765.
5. Szczeklik A, Nizankowska E, Duplaga M, AIANE Investigators: Natural history of aspirin-induced asthma. Eur Respir J 2000;16:432-436.
6. 4 in bronchial asthma. Eur Respir J 1992;5:693-699.
7. 4 concentrations increase after aspirin challenge in asthmatic subjects. Am Rev Respir Dis 1991;143:1025-1029.
8. Nasser SM, Pfister R, Christie PE, Sousa AR, Barker J, Schmitz-Schumann M, Lee TH: Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-96.
9. Nasser SM, Christie PE, Pfister R, Sousa A, Walls A, Schmitz-Schumann M, Lee TH: Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996;51:64-70.
10. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-846.
11. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-1600.
12. Kowalski ML, Lewandowska-Polak A, Woźniak J, Ptasińska A, Jankowski A, Wa̧growska-Danilewicz M, Danilewicz M, Pawliczak R: Association of stem cell factor expression in nasal polyp epithelial cells with aspirin sensitivity and asthma. Allergy 2005;60:631-637.
13. 1 receptor. Nature 1999;399:789-793.
14. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-30536.
15. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH: Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-1499.
16. 2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005;115:316-322.
17. 4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995;151:1326-1330.
18. 4) and histamine in aspirin-sensitive asthmatic subjects. Eur Respir J 1993;6:1468-1473.
19. Christie PE, Smith CM, Lee TH: The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-958.
20. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-1451.
21. Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
22. Chandrasekharan NV, Dai H, Roos LT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931.
23. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, et al: Biochemical and clinical evidence that aspirinin-tolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-1121.
24. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-225.
25. Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR: Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol (Paris) 2004;36:215-218.
26. Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z: Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps: a challenge-proven study. Int Arch Allergy Immunol 2007;142:64-69.
27. 2 on allergic airway responses in the rat. J Immunol 2002;169:3963-3969.
28. 3-dependent mechanism. J Immunol 2000;165:6545-6552.
29. 2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90.
30. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT: Regulation of Ig-induced eosinophil degranulation by adenosine 3′,5′-cyclic monophosphate. J Immunol 1991;146:2712-2718.
31. Alam R, Dejarnatt A, Stafford S, Forsythe PA, Kumar D, Grant JA: Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog: results of a double-blind, placebo-controlled randomized study. Am Rev Respir Dis 1993;148:1066-1070.
32. Peters SP, Schulman ES, Schleimer RP, MacGlashan DW Jr, Newball HH, Lichtenstein M: Dispersed human lung mast cells: pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis 1982;126:1034-1039.
33. 2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001;31:1615-1622.
34. 4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153:572-575.
35. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P: Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 2002;62:250-256.
36. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
37. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, Kornatowski T, Kaliner MA: Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-398.
38. 2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003;111:1041-1048.
39. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
40. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH: Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006;117:312-318.
41. 1: therapeutic potential for wound healing. Arch Dermatol Res 1995;287:539-545.
42. 2 regulates wound closure in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2001;280:L421-L431.
43. 2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 2006;147:707-713.
44. 2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 2004;13:3203-3217.
45. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, Kornatowski T, Kaliner MA: Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-398.
46. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J, Pawliczak R, Dubuske L: Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005;60:1139-1145.
47. 4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992;145:1281-1284.
48. 4. Nat Med 2002;8:1018-1023.
49. 4 and N-formyl-L- methionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond) 1989;77:195-203.
50. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16:44-49.
51. Fiorucci S, Distrutti E, de Lima OM, Romano M, Mencarelli A, Barbanti M, Palazzini E, Morelli A, Wallace JL: Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003;17:1171-1173.
52. 4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 2003;170:2688-2694.